A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

This trial is a registrational Phase II/III randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1/VEGF bispecific antibody in first-line patients with locally advanced or metastatic squamous non-small cell lung cancer.

Trial Details

NCT ID
NCT07739199
Phase
PHASE2 / PHASE3
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • BL-B01D1
  • PD-1/VEGF bispecific antibody
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • Age ≥18 years;
  • Expected survival time ≥3 months;
  • Patients with locally advanced or metastatic squamous non-small cell lung cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →